Short answer
Nurix Therapeutics, Inc. (NRIX) filed its Q2 2026 10-Q quarterly report on Jul 9, 2026 for the quarter ended May 31, 2026. Quarterly revenue was $9M (down 79.5% year over year) with net income of −$90M.
Q2 2026 key financials · XBRL
- Revenue
- $9M
- −79.5% YoY · +44.6% QoQ
- Net income
- −$90M
- −106.0% YoY · −2.7% QoQ
- Operating margin
- -1041.7%
- EPS (diluted)
- −$0.81
- −55.8% YoY · −2.5% QoQ
Source: XBRL data from the Nurix Therapeutics, Inc. (NRIX) Q2 2026 10-Q on SEC EDGAR. USD.
Nurix Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material-change comparison disclosed; filing carries forward early-stage clinical-development risk for bexobrutideg, zelebrudomide and NX-1607
- Capital needs: $443.5 million cash, equivalents and marketable securities at May 31, 2026, funding operations through at least 12 months
- Regulatory risk: FDA, EMA or other authorities may require additional trials, increasing development costs and delaying approvals
- Operational risk: inadequate drug supply or quality may delay clinical trials, including from third-party manufacturing failures
- Financial risk: $176.7 million six-month net loss and $1.2 billion accumulated deficit underscore dependence on additional financing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nurix Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.